Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Gastroenterology | Family Medicine
Disease Category: Colorectal Cancer
Location: United States, WA
Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With Metastatic Colorectal Cancer
The purpose of this study is to assess if regorafenib when given in combination with FOLFIRI chemotherapy will result in increased survival without the cancer getting worse as compared to placebo given in combination with FOLFIRI.
Patient Inclusion Criteria:
Patient Exclusion Criteria:
CW ID: 183334
Date Last Changed:
July 16, 2013
Christine Goetz, BA; CCRCMultiCare Health System314 Martin Luther King, Jr. Way, Suite 402Tacoma, WA 98405Phone: 253-403-7193
MultiCare Health System
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
We value your privacy and your information will only be used by the research center to contact
you regarding this study.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2017 CenterWatch.